Akums Drugs and Pharmaceuticals Limited — Investor Meet, 19-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Akums reported strong Q3 FY26 results with operating revenue up 14.8% YoY to ₹1,160 crore and PAT up 2.1% to ₹68 crore. CDMO revenue grew 16.3% YoY, driven by broad-based volume recovery and improved margins, which looks sustainable. International branded formulations saw significant QoQ growth. The API business curtailed losses, with efforts aimed at breakeven. Key future drivers include the EU CDMO contract (potential EUR 35 million annually from FY28) and the Zambia project ($25 million annual supplies from H1 FY27). Management focuses on efficiency, innovation, and strategic partnerships, actively evaluating acquisitions.